Immune Cell Therapy Drugs Market Size, Share, and Industry Analysis By Drug (Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Ciltacabtagene Autoleucel, Sipuleucel-T, Idecabtagene Vicleucel Lisocabtagene Maraleucel, Tisagenlecleucel, Lifileucel, and Others), By Indication (Lymphoma, Myeloma, Leukemia, and Others), By End-user (Hospitals and Oncology Treatment Centers), and Regional Forecast, 2026-2034

The global immune cell therapy drugs market is witnessing significant growth due to the increase in the number of cancer cases, especially hematological malignancies, which has created a demand for innovative treatments such as immune cell therapy. Furthermore, significant advancements in genetic engineering and synthetic biology have enabled the development of more effective and targeted therapies, enhancing their efficacy against resistant cancer types, which is expected to boost the market growth.

• For instance, according to an article published by the National Center for Biotechnology Information (NCBI), in January 2023, around 1,958,310 new cancer cases were projected to occur in the U.S.

Immune Cell Therapy Drugs Market Driver

Rising Incidence of Cancer Boosts the Market Growth

In recent years, the burden of cancer has been increasing significantly across the globe. Several conventional cancer treatments, such as chemotherapy and radiation, often have limited effectiveness against advanced-stage or high-risk cancers. In contrast, immune cell therapies, particularly CAR T-cell therapy, have shown promising results in treating hematological malignancies and are being researched for solid tumors. This is expected to spur the demand for immune cell therapy drugs for cancer treatment, driving the market growth over the coming years.

• For instance, in February 2024, the World Health Organization reported that there were an estimated 20.0 million new cancer cases in 2022 and this number is projected to rise to 35.0 million by 2050, representing an increase of 77.0% compared to 2022.

Download Free sample to learn more about this report.

In 2023, there were an estimated 184,720 leukemia, lymphoma, and myeloma cases in the U.S., among which lymphoma ranked the highest with a proportion of 48.0%.

Immune Cell Therapy Drugs Market Restraint

Limited Approvals and High Costs May Hinder the Market Growth

Despite promising results, only a few cell therapies, such as CAR-T for cancers, have been approved by the FDA so far, which is limiting its expansion globally. Furthermore, the high costs of immune cell therapies, especially autologous CAR-T cells, and the appearance of potentially life-threatening severe adverse effects such as cytokine release syndrome (CRS) and neurotoxicity is a barrier to its wider adoption, which is expected to hinder the market growth during the forecast period.

• For instance, as per an article published by the Journal of Hematology & Oncology in August 2023, tumor-infiltrating lymphocyte (TIL) therapy has yet to be approved for hematological cancer by the U.S. FDA owing to its numerous limitations.

Immune Cell Therapy Drugs Market Opportunity

Emerging Applications and Technological Advancements

Over the recent years, immune cell therapy drugs, particularly those utilizing CAR (Chimeric Antigen Receptor) technology, are expanding significantly beyond their initial applications in oncology. This shift could lead to significant clinical benefits as some diseases may require less aggressive therapeutic approaches compared to cancer. Furthermore, innovations in gene editing and cell manufacturing processes are expected to enhance the efficacy and safety of immune cell therapies, making them more appealing for a broader range of diseases.

• For instance, according to the National Center for Biotechnology Information (NCBI) in February 2022, recent studies suggest that CAR T cell therapies can be adapted for treating various non-cancerous conditions, such as cardiometabolic disorders, autoimmune diseases, and fibrosis.

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/Region, 2023
• Key Industry Developments (Mergers, Acquisitions & Partnerships), By Key Players
• Pipeline Analysis, By Key Players
• New Product Launches/Approvals, By Key Players
• Technological Advancements in Immune Cell Therapy Drugs Market
• Impact of COVID-19 on the Market

Segmentation

Analysis by Drug

Based on drug, the market is segmented into axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, sipuleucel-t, idecabtagene vicleucel lisocabtagene maraleucel, tisagenlecleucel, lifileucel, and others

The axicabtagene ciloleucel segment is expected to hold a major share of the global market. The growth of the segment can be attributed to the high significance of axicabtagene ciloleucel in the treatment of lymphoma. In order to spread awareness regarding this significance, prominent players are implementing various strategies to highlight the potential benefits of using this drug, which is expected to spur its adoption, boosting segment growth.

• For instance, in June 2024, Kite, a Gilead Sciences, Inc. company, represented new clinical research and real-world evidence demonstrating the potential benefits of using Yescarta (axicabtagene ciloleucel) in earlier lines of treatment for relapsed/refractory large B-cell lymphoma.

Analysis by Indication

By indication, the market is categorized into lymphoma, myeloma, leukemia, and others.

The lymphoma segment accounts for the largest share of the market. The growth of the segment is attributable to the high incidence of lymphoma among hematological cancers, which is encouraging key players to ensure the availability of immune cell therapy drugs in the market.

• For instance, in 2023, the American Cancer Society reported that the combined prevalence of leukemia, lymphoma, and myeloma was 184,720 in the U.S., among which lymphoma accounted for 48.0% of the total prevalence.

Analysis by End-user

By end-user, the market is categorized into hospitals and oncology treatment centers.

The hospitals segment accounts for the major portion of the immune cell therapy drugs market in 2023. The growth can be attributed to the increasing preference of patients to opt for drugs in hospitals as they require specialized monitoring. As a result, patient visits for cancer treatment, including immune cell therapy drugs, are rising in the hospitals, which is projected to fuel the segment growth.

• For instance, in November 2022, India's second-largest hospital chain, Manipal Hospitals, saw more than 400,000 patient visits annually for cancer treatment.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global immune cell therapy drugs market in 2023. The growth of the market is attributed to the high burden of hematological cancer, which is leading to high drug penetration in the region.

• For instance, the American Cancer Society reported that there were an estimated 9.4% cases of leukemia, lymphoma, and myeloma of the total cancer cases (1,958,310) diagnosed in the U.S. in 2023.

Europe is the second-largest market based on the demand for immune cell therapy drugs. The growth can be attributed to the significant presence of key players and well-established healthcare infrastructure that is expected to surge the adoption of immune cell therapy drugs in the region.

The Asia Pacific is expected to grow substantially over the forthcoming years. The large patient pool for cancer, including blood cancers, coupled with a high aging population and awareness of immune cell therapy drugs in the region, is anticipated to surge the number of product approvals in the region. Such a scenario is expected to propel the regional market growth.

Key Players Covered

The global market is fragmented, with a significant number of companies offering various types of immune cell therapy drugs.

The report includes the profiles of the following key players:

• Gilead Sciences, Inc. (U.S.)
• Dendreon Pharmaceuticals LLC. (U.S.)
• Ferring (Switzerland)
• IOVANCE Biotherapeutics, Inc. (U.S.)
• Bristol Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)

Key Industry Developments

• In March 2024, Bristol-Myers Squibb Company received the U.S. FDA approval for Breyanzi, a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
• In February 2024, BioNTech SE and Autolus Therapeutics entered into a strategic collaboration to advance both companies’ autologous CAR-T programs toward commercialization and pending regulatory authorizations.